Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mylan agreed to pay...

    Mylan agreed to pay $96.5 million in Provigil antitrust class action

    Written by supriya kashyap kashyap Published On 2017-02-09T11:22:10+05:30  |  Updated On 9 Feb 2017 11:22 AM IST

    Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.


    The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court.


    The money will go to purchasers that bought brand-name Provigil from Cephalon directly, like wholesalers and distributors.


    Mylan spokeswoman Nina Devlin said in an emailed statement that the settlement was not an admission of wrongdoing.


    "Mylan believes the proposed settlement is in the best interests of the company and is an important step in moving forward," she said.


    Shares of Mylan were up 2 percent at $40 in early afternoon trade on the Nasdaq.


    A group of direct purchasers sued Mylan, Cephalon and two other companies Teva - Pharmaceutical Industries Ltd and Ranbaxy Laboratories Ltd - in 2006. They brought their case on behalf of a nationwide class of direct purchasers.


    The purchasers said Cephalon reached settlements in patent lawsuits it brought against Teva, Mylan and Ranbaxy in which it paid them to keep generic versions of Provigil off the market until 2012. The lawsuit said the settlements, reached in 2005 and 2006, violated federal antitrust law.


    Teva bought Cephalon in 2011. In April 2015, it settled with the direct purchasers for $512 million.


    In May 2015, it agreed to pay $1.2 billion to settle similar claims by the U.S. Federal Trade Commission, which had separately sued Cephalon over the Provigil settlements.


    The agency has long criticized so-called "pay-for-delay" settlements in which brand-name drug makers pay their generic counterparts to keep drugs off the market.


    Ranbaxy is not a party to the settlement announced on Friday.


    The case is King Drug Company of Florence Inc, on behalf of itself and all others similarly situated, v. Cephalon Inc et al, U.S. District Court, Eastern District of Pennsylvania, No. 2:06-cv-01797.

    CephalonMylanNina DevlinRanbaxyTevaUS Federal Trade Commission
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok